Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 268 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: MedImmune LLC Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

NCT00480155
View directory record Official record
Conditions
Healthy
Interventions
Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

NCT02334306
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
AMG 557/MEDI5872, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
San Francisco, California • Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

NCT01248949
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Interventions
MEDI3617, Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

NCT00125944
View directory record Official record
Conditions
Healthy, Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
San Diego, California • Daytona Beach, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2007 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

NCT01284231
View directory record Official record
Conditions
Gastrointestinal Adenocarcinomas
Interventions
MEDI-565
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930
View directory record Official record
Conditions
Prostate Cancer
Interventions
MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
36
States / cities
Hoover, Alabama • Springdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 9, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

NCT02938793
View directory record Official record
Conditions
Cancer, Rare Disease
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults

NCT00945893
View directory record Official record
Conditions
Healthy
Interventions
MEDI3414 [Influenza A/H1N1 live attenuated, intranasal], Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study, Tremelimumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NCT03164772
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, NSCLC
Interventions
Durvalumab, Tremelimumab, BI 1361849, PharmaJet Tropis® device
Drug · Biological · Device
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

NCT02601560
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
MEDI6012, Placebo SC, Placebo IV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Results available

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361
View directory record Official record
Conditions
Cancer
Interventions
MEDI-573
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

NCT00270790
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Amifostine, Carboplatin, Taxol, Radiotherapy
Drug · Device
Lead sponsor
Mohan Suntharalingam
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Results available

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00586924
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 9, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

NCT02485990
View directory record Official record
Conditions
Primary Peritoneal Carcinoma
Interventions
Tremelimumab, Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

NCT00493285
View directory record Official record
Conditions
Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 23 Months
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
30
States / cities
Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 9, 2026, 5:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

NCT01268059
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, MEDI-575
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fountain Valley, California • Oxnard, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Randomized Amifostine For SCCHN

NCT00095927
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions
Amifostine, Carboplatin, Paclitaxel, radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

NCT00116168
View directory record Official record
Conditions
Healthy
Interventions
MEDI-528 0.3 mg/kg, MEDI-528 1 mg/kg, MEDI-528 3 mg/kg, MEDI-528 9 mg/kg
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 49 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
New Orleans, Louisiana • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

NCT00284817
View directory record Official record
Conditions
Cancer
Interventions
MEDI-522
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Early Phase 1 Interventional

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

NCT01861340
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, and MEDI-551
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

NCT00512486
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Denver, Colorado • North Darthmouth, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2008 · Synced Oct 9, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

NCT00240877
View directory record Official record
Conditions
Influenza
Interventions
AV024, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Oct 9, 2026, 5:28 PM EDT